



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

August 11, 2021

Robert Hariri, M.D., Ph.D.
Chief Executive Officer
Celularity Inc
170 Park Ave
Florham Park, New Jersey 07932

Re: Celularity Inc
Registration Statement on Form S-1
Filed August 6, 2021
File No. 333-258600

Dear Dr. Hariri:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Dillon Hagius at 202-551-7967 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Yoon-jee Kim